Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.

NCT07645430 | Completed DMC

• 1 other identifier: RC-1-24
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this study was to evaluate the change in serum interferon gamma and Interleukin-15 levels before and after use of oral drug baricitinib therapy. Venous blood samples (5 mL) were collected from each participant at baseline and at six months.

Conditions

Alopecia Areata

Keywords

Alopecia Areata; Baricitinib; Interleukin-15; Interferon Gamma

Outcome Measures

Primary Outcomes (2)

• Serum level of Interleukin-15.

  Measuring the serum level of Interleukin-15 at baseline and immediately after 6 months of Baricitinab 4mg oral therapy. Measurement is done using Enzyme-Linked Immunosorbent Assay (ELISA) laboratory technique.

  At baseline and immediately after 6 months of follow up.

• Serum level of Interferon Gamma.

  Measuring the serum level of Interferon Gamma at baseline and immediately after 6 months of Baricitinab 4mg oral therapy. Measurement is done using Enzyme-Linked Immunosorbent Assay (ELISA) laboratory technique.

  Baseline and immediately after 6 months of Baricitinab 4mg oral therapy.

Secondary Outcomes (1)

• Changes in the Severity of Alopecia Tool (SALT) score

  At Baseline and immediately after 6 months of oral Baricitinab 4mg oral therapy.

Study Arms (1)

Alopecia Areata adults with severity of alopecia tool more than 50 percent.

ACTIVE COMPARATOR

Adults aged between 18 to 50 years and having a severity of alopecia tool (SALT) score more than 50 pecent.

Drug: Baricitinib 4 MG Oral Tablet

Interventions

Baricitinib 4 MG Oral Tablet DRUG

All cases will use oral Baricitinab 4mg daily dose for six months.

Alopecia Areata adults with severity of alopecia tool more than 50 percent.

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Adults diagnosed clinically with Alopecia Areata.
• Severity of alopecia tool (SALT) score greater than 50.
• Only patients with disease duration exceeding six months but less than eight years will be included.

You may not qualify if:

• Patients were excluded if they were pregnant or lactating, and had chronic hepatic or renal disease.
• Cases diagnosed with malignancy, scalp infections, or other types of alopecia will also excluded from the current study.
• Recent use of systemic treatment within the last 3 months or topical treatment within the last 4 weeks also will be excluded.

Sponsors & Collaborators

• Benha University: lead

Study Sites (1)

Faculty of medicine, Benha University (Dermatology department)

Banhā, 13511, Egypt

Location

MeSH Terms

Conditions

Alopecia Areata

Interventions

baricitinib

Condition Hierarchy (Ancestors)

Alopecia; Hypotrichosis; Hair Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Amal Youssif Habashy, MD

  Benha University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Amal Youssif Habashy

Study Record Dates

• First Submitted: June 9, 2026
• First Posted: June 12, 2026
• Study Start: January 1, 2023
• Primary Completion: January 1, 2024
• Study Completion: June 9, 2026
• Last Updated: June 12, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)